Vyluma’s Navneet Puri and Raul Trillo Discuss CHAMP Study Results

sponsored content

November 1, 2022

Review of Myopia Management’s Chief Medical Editor Dwight Akerman, OD, MBA, FAAO, FBCLA, FIACLE, interviewed Vyluma executives Navneet Puri, PhD, Founder, Chairman, and Chief Executive Officer, and Raul Trillo, MD, MBA, Chief Commercial Officer at the American Academy of Optometry’s Annual Meeting in San Diego to learn more about the results from the company’s three-year CHAMP (Childhood Atropine for Myopia Progression) Study.

Building off the company’s presentation of the results from CHAMP, Dr. Puri and Dr. Trillo shared more insights on the design of the clinical trial, Vyluma’s interest in developing the NVK002 formula, and what the future holds for the study and gaining regulatory approval for the product.

To learn more about Vyluma’s CHAMP Study, read this Q&A with Dr. Puri, Dr. Trillo, and Karla Zadnik, OD, PhD, Principal Investigator.

To Top